Amicus Therapeutics Secures Final French Regulatory Clearance for BioMarin Merger, Expected to Close April 27
summarizeSummary
Amicus Therapeutics announced it has received final French regulatory clearance for its merger with BioMarin Pharmaceutical Inc., with the transaction now expected to close on April 27, 2026.
check_boxKey Events
-
Final Regulatory Clearance Received
The Ministry of Economics and Finance in France granted clearance for the merger with BioMarin Pharmaceutical Inc., satisfying the final regulatory condition required for the transaction.
-
Merger Expected to Close Soon
With the final regulatory condition met, the merger is now expected to close on April 27, 2026, marking the culmination of the acquisition process initiated on December 19, 2025.
auto_awesomeAnalysis
This filing confirms the successful navigation of a critical regulatory hurdle, paving the way for the merger's completion. The impending closure of the BioMarin acquisition will fundamentally alter Amicus Therapeutics' operational and financial landscape, integrating it into a larger pharmaceutical entity. This final clearance removes significant uncertainty surrounding the transaction.
At the time of this filing, FOLD was trading at $14.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $5.51 to $14.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.